| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Palbociclib (JAN/USAN); Ibrance (TN) | ||||||||
| Product | IBRANCE (Pfizer Laboratories Div Pfizer), IBRANCE (Pfizer Laboratories Div Pfizer), IBRANCE (U.S. Pharmaceuticals), IBRANCE (US Pharmaceuticals) | ||||||||
| Formula | C24H29N7O2 | ||||||||
| Exact mass | 447.2383 | ||||||||
| Mol weight | 447.5328 | ||||||||
| Structure |  | ||||||||
| Simcomp | |||||||||
| Class | Antineoplastic DG03138 CDK inhibitor | ||||||||
| Remark |
| ||||||||
| Efficacy | Antineoplastic, Cyclin-dependent kinase (CDK) inhibitor | ||||||||
| Disease | Breast cancer (HR positive, HER2 negative) [DS:H00031] | ||||||||
| Target | CDK4/6 [HSA:1019 1021] [KO:K02089 K02091] | ||||||||
| Pathway |
| ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EF Cyclin-dependent kinase (CDK) inhibitors L01EF01 Palbociclib D10372 Palbociclib (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Palbociclib D10372 Palbociclib (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D10372 Palbociclib (JAN/USAN) Drug groups [BR:br08330] Antineoplastic DG03138 CDK inhibitor DG01831 Palbociclib D10372 Palbociclib Drug classes [BR:br08332] Antineoplastic DG03138 CDK inhibitor D10372 Palbociclib Target-based classification of drugs [BR:br08310] Protein kinases Serine/threonine kinases CMGC group CDK4/6 D10372 Palbociclib (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10372 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10372 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10372 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10372 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D10372 Drug groups [BR:br08330] Antineoplastic DG03138 CDK inhibitor DG01831 Palbociclib | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 33 1 C1x C 26.9500 -22.2600 2 N1x N 26.9500 -20.8600 3 C1x C 25.6900 -20.1600 4 C1x C 24.5000 -20.8600 5 N1y N 24.5000 -22.2600 6 C1x C 25.6900 -22.9600 7 C8y C 23.2400 -23.0300 8 C8x C 22.0500 -22.3300 9 C8x C 20.8600 -23.0300 10 C8y C 20.8600 -24.4300 11 N5x N 22.0500 -25.1300 12 C8x C 23.2400 -24.4300 13 N1b N 19.6000 -25.1300 14 C8y C 18.4100 -24.4300 15 N5x N 18.4100 -22.9600 16 C8y C 17.2200 -22.2600 17 C8y C 15.9600 -22.9600 18 C8x C 15.9600 -24.4300 19 N5x N 17.2200 -25.1300 20 N4y N 17.2200 -20.8600 21 C8y C 15.9600 -20.1600 22 C8y C 14.7700 -20.8600 23 C8y C 14.7700 -22.2600 24 C1y C 18.4100 -20.1600 25 C5a C 13.5800 -20.1600 26 C1a C 12.3900 -20.8600 27 O5a O 13.5800 -18.7600 28 O5x O 15.9600 -18.7600 29 C1a C 13.5800 -22.9600 30 C1x C 19.7374 -20.6050 31 C1x C 20.5708 -19.4801 32 C1x C 19.7585 -18.3398 33 C1x C 18.4230 -18.7600 BOND 37 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 5 7 1 8 7 8 2 9 8 9 1 10 9 10 2 11 10 11 1 12 11 12 2 13 7 12 1 14 10 13 1 15 13 14 1 16 14 15 2 17 15 16 1 18 16 17 2 19 17 18 1 20 18 19 2 21 14 19 1 22 16 20 1 23 20 21 1 24 21 22 1 25 22 23 2 26 17 23 1 27 20 24 1 28 22 25 1 29 25 26 1 30 25 27 2 31 21 28 2 32 23 29 1 33 24 30 1 34 30 31 1 35 31 32 1 36 32 33 1 37 24 33 1 |